Tag: psychedelics

Helping veterans, battling opioid addiction driving magic mushroom legislation progress

Forty lawmakers, 36 Democrats and 4 Republicans, have co-sponsored a bill aiming to allow for the medical use of psilocybin and a psilocybin therapy grant program, which is currently sitting at the committee level of the Assembly, with its Senate version also in committee. The Assembly bill, A03581, was introduced by Democrat Pat Burke in February. There has been other legislation introduced regarding the hallucinogen as well, with Linda Rosenthal’s version legalizing the adult possession and use of hallucinogens like it.

Research has shown that psilocybin, an organic psychedelic compound, can benefit people with cluster headaches, depression, anxiety, irritable bowel syndrome, ADHD and obsessive compulsive disorder, but it’s getting the most universal traction because of its impact on those suffering from PTSD.

“Psilocybin doesn’t have the huge appeal that marijuana had,” Democrat Assemblyman Phil Steck, who is the Assembly’s Chairman of the Alcoholism and Drug Abuse Committee, says. “But, there are definitely people who make a strong case for the proposition that it helps with PTSD. Certainly we want to do everything that we can to help people that are coming back from war, and if psilocybin has proven to do that, then it should be legal for that purpose.”

Johns Hopkins University has conducted several studies on psilocybin, saying it has substantial antidepressant effects, but needs to be administered under carefully controlled conditions through trained clinicians and therapists.

Keep reading

US could soon approve MDMA therapy — opening an era of psychedelic medicine

For Rick Doblin, 2023 could be a landmark year: the year that the US government decides whether it will allow the use of hallucinogenic drugs to treat mental illness.

Doblin, who is based in Belmont, Massachusetts, is the founder and president of the non-profit organization Multidisciplinary Association for Psychedelic Studies (MAPS). He has spent nearly 40 years researching whether the experience produced by the psychedelic drug MDMA — also called ecstasy or molly — can help people with post-traumatic stress disorder (PTSD). In 2021, MAPS’s phase III clinical trial of 90 people with PTSD found that those who received MDMA coupled with psychotherapy were twice as likely to recover from the condition as were those who received psychotherapy with a placebo1 (see ‘Response to MDMA therapy’).

Keep reading

Celebrating The 80th Anniversary Of Bicycle Day: A Different Kind Of Trip

Every year, on April 19, an important anniversary rolls around that you may never have heard of. To those in the know, it’s called Bicycle Day, and it commemorates the first-ever intentional LSD trip. 

It all started when a Swiss chemist called Albert Hofmann had a very peculiar time while cycling home from the lab. Hofmann was the first person to synthesize LSD back in 1938. He did it by isolating chemical compounds found in a fungus called ergot, which infects grasses like rye and can have some profound effects on any humans unfortunate enough to accidentally consume it.

It’s safe to say that Hofmann didn’t think much of his discovery to begin with. What we now know as LSD was actually the 25th in a long line of similar compounds that he’d been experimenting with, and Hofmann’s research notes from the time reportedly reveal how no one was particularly enthused by it: “The new substance, however, aroused no special interest in our pharmacologists and physicians; testing was therefore discontinued.”

Keep reading

NEVADA COMMITTEE TO VOTE ON BILL FOR RESEARCH, DECRIMINALIZATION OF PSILOCYBIN

Greg Rea had his first experience with psychedelics when he was 56 years old. Up until then, he’d been a Reno police officer on SWAT for 12 years before retiring from the force to become a pastor and then a real estate investor.

“I retired a couple years ago, but I still was a pretty tightly wound guy,” Rea tells the Weekly in a phone interview. “And I had a seven-days-a-week drinking problem.”

Rea says that despite having a “pretty good life,” like many first responders, alcohol use was adversely affecting him—until about three years ago, when a friend invited him to a group psychedelic experience.

During that experience, which comprised several sessions, a combination of psilocybin [the drug in “magic” mushrooms] and MDMA [aka ecstasy or Molly]took Rea back to two “fairly violent, critical incidents” in which he was involved as a SWAT officer. The intense, emotional trip led to a breakthrough, he says.

“I realized I had some form of PTSD connected to those things,” Rea says. “And I had no idea I’d carried it for almost 20 years.”

After group sessions with other first responders, he began to find a community to talk about mental health—“inner world things” that the wider community might misunderstand. “First responders are exposed to an inordinate amount of human suffering [that] the typical citizen isn’t. So, we said, why don’t we start our own group?”

In the group, firefighters, first responders and current and former military service members are opening up and “finding their healing with psychedelic medicine,” he says. “And I’m free from my seven-days-a-week alcohol habit. My life is just inordinately better. And my relationships are better.”

Rea was one of many who gave public comment during a March 23 hearing for Senate Bill 242 (SB242).

In his testimony, Assemblyman Max Carter said that his therapy with ketamine, the only drug currently legal for psychedelic therapy, has been “transformational” in his mental health and struggle with chronic depression.

“Psilocybin, studies show, is much more powerful. Where I’ve gone through eight or nine ketamine sessions, [it] probably would have been one or two [sessions], if psilocybin was legal,” Carter said, adding that, based on studies, the effects of psilocybin appear to be longer lasting than ketamine.

The bill would establish a framework for research of psilocybin in the state and, if passed as amended, decriminalize possession of the substance, currently listed as a Schedule 1 drug.

Keep reading

Colorado steps off into the world of ‘magic mushrooms’

It is being hailed as everything from the beginning of a journey to the coming of a new industry, but for sure it’s a step toward legal consumption of “magic mushrooms” in Colorado. The involved event is merely a bureaucratic exercise — today’s first advisory board meeting will, over the next couple of years, move “magic mushrooms” into a legal and regulated space.

The mushrooms are usually eaten and are therefore considered a food safety issue by some. 

Psilocybin mushrooms are classified as an illegal Schedule I drug under federal law. Schedule I drugs include substances that are not recognized for medical use and that the Drug Enforcement Administration (DEA) defines as having a high potential for abuse and dependence.

The 15-member advisory board appointed by Colorado Gov. Jared Polis is supposed to make an exception for Colorado. The Natural Medicine Advisory Board will advise Colorado’s Department of Regulatory Agencies (DORA) on the manufacturing, testing, and use of psilocybin and psilocin — the psychoactive compounds in “magic mushrooms.”

In November 2022, Colorado became the second state to legalize psilocybin by passage of a ballot measure. Oregon was the first in 2020. The City and County of Denver in 2021 also approved Ordinance 301 to decriminalize the use and possession in Denver of magic mushrooms.

The Denver ordinance deprioritizes, to the greatest extent possible, the imposition of criminal penalties on anyone 21 years of age and older for the personal use and personal possession of psilocybin mushrooms; and prohibits the city and county of Denver from spending resources on imposing criminal penalties on people 21 years of age and older for the personal use and personal possession of psilocybin mushroom.

Just as it did with recreational marijuana after the 2012 voter initiative, Colorado is clearing the path to make the use of “magic mushrooms” legal. The current schedule calls for the advisory board to make its first recommendations to DORA by Sept. 30, 2023, and DORA is supposed to adopt rules and begin licensing for the centers where mushroom use will be administered one year later by Sept. 30, 2024.

Also by Jan. 1, 2024, individuals who’ve gone through required training will become eligible for licenses.

Keep reading

Psychedelic drugs were used by ancient man, new study shows

Researchers have found evidence of drug use during Bronze Age ceremonies.

Analysis of strands of human hair from a burial site on the Spanish island of Menorca indicates ancient human civilisations used hallucinogenic drugs derived from plants.

The findings are the first direct evidence of ancient drug use in Europe, which may have been used as part of ritualistic ceremonies, researchers say.

Researchers detected scopolamine, ephedrine and atropine in three replicated hair samples.

Atropine and scopolamine are naturally found in the nightshade plant family and can induce delirium, hallucinations and altered sensory perception.

Ephedrine is a stimulant derived from certain species of shrubs and pines which can increase excitement, alertness and physical activity.

Elisa Guerra-Doce, from the Universidad de Valladolid in Spain, and colleagues examined hair from the Es Carritx cave, which was first occupied around 3,600 years ago.

Writing in the Scientific Reports journal, the authors said: “Interestingly, the psychoactive substances detected in this study are not suitable for alleviating the pain involved in severe palaeopathological conditions attested in the population buried in the cave of Es Carritx, such as periapical abscesses, severe caries and arthropathies.

“Considering the potential toxicity of the alkaloids found in the hair, their handling, use and applications represented highly specialised knowledge. This knowledge was typically possessed by shamans, who were capable of controlling the side-effects of the plant drugs through an ecstasy that made diagnosis or divination possible.”

Keep reading

Psychedelic drug improves symptoms of depression for six months, finds study

A psychedelic drug that gives trips lasting half an hour improves the symptoms of moderate to severe depression for up to six months, early trial results suggest.

Biotechnology company Small Pharma announced the results of its phase 2a clinical trials of the effects of a pharmaceutical-grade formulation of Dimethyltryptamine (SPL026) on major depressive disorder, simply referred to as depression.

The drug is a powerful hallucinogenic found in several plants and is the psychoactive compound found in ayahuasca, a compound used in shamanic rituals in South America.

In the study, 34 patients were given the drug during a clinical session with supportive therapy.

The individual sessions lasted less than two-and-a-half hours, and included a preparation session with a therapist, a psychedelic experience after administering the drug (where the therapist was present) lasting less than 30 minutes, and a therapy session to help patients process their trip.

Keep reading

On the need for metaphysics in psychedelic therapy and research

The essential proposal of this text is that psychedelic-induced metaphysical experiences should be integrated and evaluated with recourse to metaphysics. It will be argued that there is a potential extra benefit to patients in psychedelic-assisted therapy if they are provided with an optional, additional, and intelligible schema and discussion of metaphysical options at the integrative phase of the therapy. This schema (the “Metaphysics Matrix”) and a new Metaphysics Matrix Questionnaire (“MMQ”) stemming therefrom will be presented, the latter of which can also be used as an alternative or additional tool for quantitative measurement of psychedelic experience in trials. Metaphysics is not mysticism, despite some overlap; and certainly not all psychedelic experience is metaphysical or mystical—all three terms will be defined and contrasted. Thereafter psychedelic therapy will be presented and analysed in order to reveal the missing place for metaphysics. Metaphysics, with epistemology (theory of knowledge) and axiology (ethics and aesthetics), is a defining branch of Philosophy. Metaphysics, in contrast to mysticism, is considered to be based on argument rather than pure revelation. Thus, in psychedelic-assisted psychotherapy one sees here the potential bridge between reason-based philosophy and practical therapy—or, more broadly, with psychedelic-assisted psychotherapy there is the potential and mutually beneficial fusion of philosophy with practical science.

Keep reading

Psychedelics and mental health: Having mystical experiences may yield strongest benefits

It’s a trope seen countless times in books and movies. A character emerges from a drug-induced psychedelic stupor with a fresh outlook and more positive perspective on life. According to new findings from The Ohio State University, however, there may really be some truth to this hallucinogenic notion. Scientists report particularly mystical and insightful psychedelic drug experiences may be associated with an enduring drop in both anxiety and depression symptoms.

Study authors performed a comprehensive machine learning analysis of data pertaining to nearly 1,000 survey respondents who answered questions about their previous non-clinical experiences with psychedelic drugs. Sure enough, those scoring the highest on questionnaires assessing the mystical and insightful nature of their experiences also consistently reported improvements in both depression and anxiety.

Of course, there’s also the risk of encountering a “bad trip.” What happens if a psychedelic experience becomes unpleasant, frightening, or destabilizing? Surprisingly, the study actually found that even challenging psychedelic trips can be beneficial — especially within the context of mystical and insightful experiences. This finding in particular may be especially helpful for practitioners to know as they guide patients through clinical trials focusing on the therapeutic potential of psychedelics.

“Sometimes the challenge arises because it’s an intensely mystical and insightful experience that can, in and of itself, be challenging,” says senior study author Alan Davis, assistant professor and director of the Center for Psychedelic Drug Research and Education in The Ohio State University College of Social Work, in a media release.

Keep reading

Ex-Mormons Are Running a Magic Mushroom Church

As he set up for Sunday services in a dank basement lined with velvet seating and glow-in-the-dark blue tables, Steve Urquhart, founder of the Divine Assembly, tried hard not to think about the swingers’ party that took place in the space the previous night. 

“They have a lot of fun. I think it’s a rowdy crowd,” Urquhart, 57, a former Republican state senator and ex-Mormon, told VICE News with a mischievous smile, looking a bit like a lumberjack with his white beard and red flannel shirt.

On Saturday nights, the New Yorker Club has “lifestyle” parties. By Sunday morning, a few upside down pineapples (the bat signal for swingers), sticky floors, one suspiciously damp spot on a couch, and tasteful nudes on the walls remained as the Divine Assembly took over the venue. Urquhart and his wife Sara founded the church three years ago, and while the idea of congregating in a club where people likely have sex may sound counterintuitive, this group is used to bucking norms. Their sacrament, which they use to commune directly with the “divine” (which could mean god, the universe, or even family members depending on the person), is psychedelic mushrooms. 

“We have one tenet, which is you, each individual, can commune with the divine and out of that direct communion, you can receive guidance,” Urquhart explained. “You don’t need any kind of intermediary, you don’t need me, you don’t need anyone.”

But no one gets high at church. Instead, congregants participate in a range of workshops and activities that include an ice bath, a meditation room with flashing lights, and a shroom growing course called “shroomiversity.” 

The Divine Assembly is one of a growing number of churches in the U.S. whose followers worship using psychedelics like shrooms, ayahuasca, peyote, and bufo (psychoactive toad venom). VICE News has identified at least 19 psychedelic churches, though more likely exist underground and will continue to pop up as these drugs become more mainstream and legal in some cities and states. The churches operate in different ways; some have formal spaces, while others rent out venues or offer monthly retreats. Some charge membership fees and provide members with drugs—others, like the Divine Assembly, don’t. All the churches believe they’re protected under freedom of religion, although few have legal exemptions to use drugs, leaving church leaders and members responsible for defending themselves, should they ever be arrested. 

Keep reading